Showing results (21-30 of 46) with videos related to
Sort By:
Pageof 5
International Journal of Clinical Pharmacology and Therapeutics|April 25, 2015
Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participantsDamayanthi Devineni, David Polidori, Christopher R Curtin, et al.Metabolism: Clinical and Experimental|August 12, 2014
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trialPeter Stein, Jolene K Berg, Linda Morrow, et al.The Journal of Biological Chemistry|April 19, 2014
Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretionArthur T Suckow, David Polidori, Wen Yan, et al.Journal of Clinical Pharmacology|May 15, 2013
Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitusDamayanthi Devineni, Christopher R Curtin, David Polidori, et al.British Journal of Clinical Pharmacology|February 1, 2017
Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozinWillem de Winter, Adrian Dunne, Xavier Woot de Trixhe, et al.Diabetes, Obesity & Metabolism|May 5, 2020
Intrahepatic fat, irrespective of ethnicity, is associated with reduced endogenous insulin clearance and hepatic insulin resistance in obese youths: A cross-sectional and longitudinal study from the Yale Pediatric NAFLD cohortDomenico Tricò, Alfonso Galderisi, Andrea Mari, et al.British Journal of Clinical Pharmacology|April 4, 2026
A phase 1 evaluation of inhaled oxytocin: Physiologically-based pharmacokinetic model informed dosing of a novel heat-stable oxytocin delivery systemPete Lambert, Carl M J Kirkpatrick, Rory Marriott, et al.Clinical Therapeutics|June 7, 2015
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese SubjectsXia Chen, Pei Hu, Nicole Vaccaro, et al.Clinical Pharmacology in Drug Development|April 30, 2016
Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on C-peptide kineticsDavid Polidori, Sue Sha, Tim Heise, et al.Plos One|October 1, 2014
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetesSue Sha, Damayanthi Devineni, Atalanta Ghosh, et al.Pageof 5